Xanomeline suppresses excessive pro-inflammatory cytokine responses through neural signal-mediated pathways and improves survival in lethal inflammation

Brain, Behavior, and Immunity

Volumn 44, Issue , 2015, Pages 19-27

  Rosas Ballina, Mauricio ^a,b   Valdés Ferrer, Sergio I ^a   Dancho, Meghan E ^a   Ochani, Mahendar ^a   Katz, David ^a   Cheng, Kai Fan ^a   Olofsson, Peder S ^a   Chavan, Sangeeta S ^a   Al Abed, Yousef ^a   Tracey, Kevin J ^a   Pavlov, Valentin A ^a  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Brain muscarinic acetylcholine receptors; Cytokines; Endotoxemia; Inflammation; Sepsis ; Sickness behavior; Splenic nerve; Vagus nerve; Xanomeline

Indexed keywords

GALANTAMINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; MUSCARINIC RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; XANOMELINE; CYTOKINE; LIPOPOLYSACCHARIDE; MUSCARINIC AGENT; MUSCARINIC M1 RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDINE DERIVATIVE; THIADIAZOLE DERIVATIVE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CYTOKINE RESPONSE; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; ILLNESS BEHAVIOR; INFLAMMATION; LYMPHOCYTE; MALE; MOUSE; NERVE TRANSECTION; NONHUMAN; PROTEIN BLOOD LEVEL; SCHIZOPHRENIA; SEPSIS; SPLEEN; SPLEEN CELL; VAGUS NERVE; AGONISTS; ANIMAL; BAGG ALBINO MOUSE; BLOOD; DRUG EFFECTS; INNERVATION; INTRAPERITONEAL DRUG ADMINISTRATION; MORTALITY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; SURVIVAL; VAGOTOMY;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYTOKINES; ILLNESS BEHAVIOR; INJECTIONS, INTRAPERITONEAL; LIPOPOLYSACCHARIDES; MALE; MICE, INBRED BALB C; MUSCARINIC AGONISTS; PYRIDINES; RATS, SPRAGUE-DAWLEY; RECEPTOR, MUSCARINIC M1; SEPSIS; SPLEEN; SURVIVAL ANALYSIS; THIADIAZOLES; TUMOR NECROSIS FACTOR-ALPHA; VAGOTOMY; VAGUS NERVE;

EID: 84918811795     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2014.07.010     Document Type: Article

References (61)

1. Andersson U., Tracey K.J. Neural reflexes in inflammation and immunity. J. Exp. Med. 2012, 209:1057-1068.
2. Bellinger D.L., Felten S.Y., Lorton D., Felten D.L. Origin of noradrenergic innervation of the spleen in rats. Brain Behav. Immun. 1989, 3:291-311.
3. Berthoud H.R., Powley T.L. Characterization of vagal innervation to the rat celiac, suprarenal and mesenteric ganglia. J. Auton. Nerv. Syst. 1993, 42:153-169.
4. Bodick N.C., Offen W.W., Levey A.I., Cutler N.R., Gauthier S.G., Satlin A., Shannon H.E., Tollefson G.D., Rasmussen K., Bymaster F.P., Hurley D.J., Potter W.Z., Paul S.M. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch. Neurol. 1997, 54:465-473.
5. Bodick N.C., Offen W.W., Shannon H.E., Satterwhite J., Lucas R., van Lier R., Paul S.M. The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease. Alzheimer Dis. Assoc. Disord. 1997, 11(Suppl. 4):S16-S22.
6. Caccamo A., Oddo S., Billings L.M., Green K.N., Martinez-Coria H., Fisher A., LaFerla F.M. M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron 2006, 49:671-682.
7. Capuron L., Miller A.H. Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol. Ther. 2011, 130:226-238.
8. Christopoulos A., Pierce T.L., Sorman J.L., El Fakahany E.E. On the unique binding and activating properties of xanomeline at the M1 muscarinic acetylcholine receptor. Mol. Pharmacol. 1998, 53:1120-1130.
9. de la Torre J.C. Standardization of the sucrose-potassium phosphate-glyoxylic acid histofluorescence method for tissue monoamines. Neurosci. Lett. 1980, 17:339-340.
10. Eberlein J., Nguyen T.T., Victorino F., Golden-Mason L., Rosen H.R., Homann D. Comprehensive assessment of chemokine expression profiles by flow cytometry. J. Clin. Invest. 2010, 120:907-923.
11. Echtenacher B., Falk W., Mannel D.N., Krammer P.H. Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J. Immunol. 1990, 145:3762-3766.
12. Echtenacher B., Hultner L., Mannel D.N. Cellular and molecular mechanisms of TNF protection in septic peritonitis. J. Inflamm. 1995, 47:85-89.
13. Echtenacher B., Mannel D.N. Requirement of TNF and TNF receptor type 2 for LPS-induced protection from lethal septic peritonitis. J. Endotoxin Res. 2002, 8:365-369.
14. Farde L., Suhara T., Halldin C., Nyback H., Nakashima Y., Swahn C.G., Karlsson P., Ginovart N., Bymaster F.P., Shannon H.E., Foged C., Suzdak P.D., Sauerberg P. PET study of the M1-agonists [11C]xanomeline and [11C]butylthio-TZTP in monkey and man. Dementia 1996, 7:187-195.
15. Fisher A., Brandeis R., Bar-Ner R.H., Kliger-Spatz M., Natan N., Sonego H., Marcovitch I., Pittel Z. AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's disease. J. Mol. Neurosci. 2002, 19:145-153.
16. Flierl M.A., Stahel P.F., Rittirsch D., Huber-Lang M., Niederbichler A.D., Hoesel L.M., Touban B.M., Morgan S.J., Smith W.R., Ward P.A., Ipaktchi K. Inhibition of complement C5a prevents breakdown of the blood-brain barrier and pituitary dysfunction in experimental sepsis. Crit. Care 2009, 13:R12.
17. Frederick B., Satlin A., Wald L.L., Hennen J., Bodick N., Renshaw P.F. Brain proton magnetic resonance spectroscopy in Alzheimer disease: changes after treatment with xanomeline. Am. J. Geriatr. Psychiatry 2002, 10:81-88.
18. Goehler L.E., Gaykema R.P., Hansen M.K., Anderson K., Maier S.F., Watkins L.R. Vagal immune-to-brain communication: a visceral chemosensory pathway. Auton. Neurosci. 2000, 85:49-59.
19. Goehler L.E., Gaykema R.P., Nguyen K.T., Lee J.E., Tilders F.J., Maier S.F., Watkins L.R. Interleukin-1beta in immune cells of the abdominal vagus nerve: a link between the immune and nervous systems?. J. Neurosci. 1999, 19:2799-2806.
20. Gomeza J., Shannon H., Kostenis E., Felder C., Zhang L., Brodkin J., Grinberg A., Sheng H., Wess J. Pronounced pharmacologic deficits in M2 muscarinic acetylcholine receptor knockout mice. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:1692-1697.
21. Grant M.K., Noetzel M.J., De Lorme K.C., Jakubik J., Dolezal V., El Fakahany E.E. Pharmacological evaluation of the long-term effects of xanomeline on the M(1) muscarinic acetylcholine receptor. PLoS ONE 2010, 5:e15722.
22. Hofer S., Bopp C., Hoerner C., Plaschke K., Faden R.M., Martin E., Bardenheuer H.J., Weigand M.A. Injury of the blood brain barrier and up-regulation of Icam-1 in polymicrobial sepsis. J. Surg. Res. 2008, 146:276-281.
23. Huston J.M., Gallowitsch-Puerta M., Ochani M., Ochani K., Yuan R., Rosas-Ballina M., Ashok M., Goldstein R.S., Chavan S., Pavlov V.A., Metz C.N., Yang H., Czura C.J., Wang H., Tracey K.J. Transcutaneous vagus nerve stimulation reduces serum high mobility group box 1 levels and improves survival in murine sepsis. Crit. Care Med. 2007, 35:2762-2768.
24. Huston J.M., Ochani M., Rosas-Ballina M., Liao H., Ochani K., Pavlov V.A., Gallowitsch-Puerta M., Ashok M., Czura C.J., Foxwell B., Tracey K.J., Ulloa L. Splenectomy inactivates the cholinergic antiinflammatory pathway during lethal endotoxemia and polymicrobial sepsis. J. Exp. Med. 2006, 203:1623-1628.
25. Ji H., Rabbi M.F., Labis B., Pavlov V.A., Tracey K.J., Ghia J.E. Central cholinergic activation of a vagus nerve-to-spleen circuit alleviates experimental colitis. Mucosal Immunol. 2014, 7:335-347.
26. Jones C.K., Byun N., Bubser M. Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia. Neuropsychopharmacology 2012, 37:16-42.
27. Kawashima K., Fujii T., Moriwaki Y., Misawa H. Critical roles of acetylcholine and the muscarinic and nicotinic acetylcholine receptors in the regulation of immune function. Life Sci. 2012, 91:1027-1032.
28. Kelley K.W., McCusker R.H. Getting nervous about immunity. Semin. Immunol. 2014, [Epub ahead of print].
29. Maehara S., Hikichi H., Ohta H. Behavioral effects of N-desmethylclozapine on locomotor activity and sensorimotor gating function in mice-possible involvement of muscarinic receptors. Brain Res. 2011, 1418:111-119.
30. McCusker R.H., Kelley K.W. Immune-neural connections: how the immune system's response to infectious agents influences behavior. J. Exp. Biol. 2013, 216:84-98.
31. McKinzie D.L., Bymaster F.P. Muscarinic mechanisms in psychotic disorders. Handb. Exp. Pharmacol. 2012, 233-265.
32. Meyer U., Schwarz M.J., Muller N. Inflammatory processes in schizophrenia: a promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond. Pharmacol. Ther. 2011, 132:96-110.
33. Mirakaj V., Dalli J., Granja T., Rosenberger P., Serhan C.N. Vagus nerve controls resolution and pro-resolving mediators of inflammation. J. Exp. Med. 2014, 211:1037-1048.
34. Olofsson P.S., Rosas-Ballina M., Levine Y.A., Tracey K.J. Rethinking inflammation: neural circuits in the regulation of immunity. Immunol. Rev. 2012, 248:188-204.
35. Parrish W.R., Rosas-Ballina M., Gallowitsch-Puerta M., Ochani M., Ochani K., Yang L.H., Hudson L., Lin X., Patel N., Johnson S.M., Chavan S., Goldstein R.S., Czura C.J., Miller E.J., Al Abed Y., Tracey K.J., Pavlov V.A. Modulation of TNF release by choline requires alpha7 subunit nicotinic acetylcholine receptor-mediated signaling. Mol. Med. 2008, 14:567-574.
36. Pavlov V.A. Cholinergic modulation of inflammation. Int. J. Clin. Exp. Med. 2008, 1:203-212.
37. Pavlov V.A., Ochani M., Gallowitsch-Puerta M., Ochani K., Huston J.M., Czura C.J., Al Abed Y., Tracey K.J. Central muscarinic cholinergic regulation of the systemic inflammatory response during endotoxemia. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:5219-5223.
38. Pavlov V.A., Ochani M., Yang L.H., Gallowitsch-Puerta M., Ochani K., Lin X., Levi J., Parrish W.R., Rosas-Ballina M., Czura C.J., Larosa G.J., Miller E.J., Tracey K.J., Al Abed Y. Selective alpha7-nicotinic acetylcholine receptor agonist GTS-21 improves survival in murine endotoxemia and severe sepsis. Crit. Care Med. 2007, 35:1139-1144.
39. Pavlov V.A., Parrish W.R., Rosas-Ballina M., Ochani M., Puerta M., Ochani K., Chavan S., Al Abed Y., Tracey K.J. Brain acetylcholinesterase activity controls systemic cytokine levels through the cholinergic anti-inflammatory pathway. Brain Behav. Immun. 2009, 23:41-45.
40. Pavlov V.A., Tracey K.J. Neural regulators of innate immune responses and inflammation. Cell. Mol. Life Sci. 2004, 61:2322-2331.
41. Pavlov V.A., Tracey K.J. The cholinergic anti-inflammatory pathway. Brain Behav. Immun. 2005, 19:493-499.
42. Pavlov V.A., Tracey K.J. Controlling inflammation: the cholinergic anti-inflammatory pathway. Biochem. Soc. Trans. 2006, 34:1037-1040.
43. Pavlov V.A., Tracey K.J. The vagus nerve and the inflammatory reflex - linking immunity and metabolism. Nat. Rev. Endocrinol. 2012, 8:743-754.
44. Pavlov V.A., Wang H., Czura C.J., Friedman S.G., Tracey K.J. The cholinergic anti-inflammatory pathway: a missing link in neuroimmunomodulation. Mol. Med. 2003, 9:125-134.
45. Raison C.L., Miller A.H. Malaise, melancholia and madness: the evolutionary legacy of an inflammatory bias. Brain Behav. Immun. 2013, 31:1-8.
46. Rittirsch D., Huber-Lang M.S., Flierl M.A., Ward P.A. Immunodesign of experimental sepsis by cecal ligation and puncture. Nat. Protoc. 2009, 4:31-36.
47. Rosas-Ballina M., Ochani M., Parrish W.R., Ochani K., Harris Y.T., Huston J.M., Chavan S., Tracey K.J. Splenic nerve is required for cholinergic antiinflammatory pathway control of TNF in endotoxemia. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:11008-11013.
48. Rosas-Ballina M., Olofsson P.S., Ochani M., Valdes-Ferrer S.I., Levine Y.A., Reardon C., Tusche M.W., Pavlov V.A., Andersson U., Chavan S., Mak T.W., Tracey K.J. Acetylcholine-synthesizing T cells relay neural signals in a vagus nerve circuit. Science 2011, 334:98-101.
49. Saito H., Sherwood E.R., Varma T.K., Evers B.M. Effects of aging on mortality, hypothermia, and cytokine induction in mice with endotoxemia or sepsis. Mech. Ageing Dev. 2003, 124:1047-1058.
50. Satapathy S.K., Ochani M., Dancho M., Hudson L.K., Rosas-Ballina M., Valdes-Ferrer S.I., Olofsson P.S., Harris Y.T., Roth J., Chavan S., Tracey K.J., Pavlov V.A. Galantamine alleviates inflammation and other obesity-associated complications in high-fat diet-fed mice. Mol. Med. 2011, 17:599-606.
51. Shannon H.E., Bymaster F.P., Calligaro D.O., Greenwood B., Mitch C.H., Sawyer B.D., Ward J.S., Wong D.T., Olesen P.H., Sheardown M.J. Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors. J. Pharmacol. Exp. Ther. 1994, 269:271-281.
52. Shekhar A., Potter W.Z., Lightfoot J., Lienemann J., Dube S., Mallinckrodt C., Bymaster F.P., McKinzie D.L., Felder C.C. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am. J. Psychiatry 2008, 165:1033-1039.
53. Steinman L. Lessons learned at the intersection of immunology and neuroscience. J. Clin. Invest. 2012, 122:1146-1148.
54. Su X., Matthay M.A., Malik A.B. Requisite role of the cholinergic alpha7 nicotinic acetylcholine receptor pathway in suppressing gram-negative sepsis-induced acute lung inflammatory injury. J. Immunol. 2010, 184:401-410.
55. Swirski F.K., Nahrendorf M., Etzrodt M., Wildgruber M., Cortez-Retamozo V., Panizzi P., Figueiredo J.L., Kohler R.H., Chudnovskiy A., Waterman P., Aikawa E., Mempel T.R., Libby P., Weissleder R., Pittet M.J. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 2009, 325:612-616.
56. Tracey K.J. The inflammatory reflex. Nature 2002, 420:853-859.
57. Tracey K.J. Physiology and immunology of the cholinergic antiinflammatory pathway. J. Clin. Invest. 2007, 117:289-296.
58. Tracey K.J. Reflex control of immunity. Nat. Rev. Immunol. 2009, 9:418-428.
59. Valdes-Ferrer S.I., Rosas-Ballina M., Olofsson P.S., Lu B., Dancho M.E., Li J., Yang H., Pavlov V.A., Chavan S.S., Tracey K.J. High-mobility group box 1 mediates persistent splenocyte priming in sepsis survivors: evidence from a murine model. Shock 2013, 40:492-495.
60. Valdes-Ferrer S.I., Rosas-Ballina M., Olofsson P.S., Lu B., Dancho M.E., Ochani M., Li J.H., Scheinerman J.A., Katz D.A., Levine Y.A., Hudson L.K., Yang H., Pavlov V.A., Roth J., Blanc L., Antoine D.J., Chavan S.S., Andersson U., Diamond B., Tracey K.J. HMGB1 mediates splenomegaly and expansion of splenic CD11b+ Ly-6C(high) inflammatory monocytes in murine sepsis survivors. J. Intern. Med. 2013, 274:381-390.
61. Vincent J.L., Opal S.M., Marshall J.C., Tracey K.J. Sepsis definitions: time for change. Lancet 2013, 381:774-775.